Opinion|Videos|May 2, 2025
Evaluating the Role of Cu-PSMA PET Imaging in Prostate Cancer
Panelists discuss how, Copper-64 (^64Cu)–labeled PSMA-targeted PET imaging is emerging as a promising modality in prostate cancer diagnosis. The phase 2 SOLAR study (NCT05653856) demonstrated that ^64Cu-PSMA I&T PET/CT effectively detects metastatic prostate cancer, meeting primary end points related to correct localization rates. Compared with gallium-68 (^68Ga) and fluorine-18 (^18F), ^64Cu offers a half-life of approximately 12.7 hours, facilitating centralized production and distribution, which may improve accessibility
Advertisement
Video content above is prompted by the following:
- Discuss the emerging role of CU-PSMA-targeted PET imaging in prostate cancer.
- SOLAR phase 2 study – Cu-64-PSMA I&T (NCT05653856)
- 61Cu-PSMA–targeted PET for prostate cancer (Bernabeu et al. J Nucl Med. 2024)
- How do copper isotopes compare with others (gallium and fluorine) in terms of half-life, production logistics, image quality, etc?
- What potential advantages may copper-based isotopes offer over gallium or fluorine isotopes?
- Where do you see Cu-PSMA–targeted PET fitting in the current treatment landscape, and how might it influence future treatment approaches in prostate cancer?
Advertisement
Related to this article
Bhanu Prasad Venkatesulu, MBBS, MD, discussed why fewer radiation oncologists offer prostate brachytherapy and the patients for whom he still recommends it.
In a retrospective study, high AI-derived whole-body tumor volume on PSMA PET-CT was associated with a 3.20-fold higher risk of death in prostate cancer.
In a prospective cohort, a 3-gene blood model predicted 1-year castration resistance with an AUC of 0.89 in metastatic hormone-sensitive prostate cancer.
ASTRO now recommends moderate hypofractionation for all risk groups and SBRT as a standard option in low- and intermediate-risk localized prostate cancer.
Advertisement
Advertisement
Trending on CancerNetwork
1
What Separates a Next-Generation Liver Tumor Board From the Traditional Model?
2
Weighing Immunotherapy for Bridging and Downstaging Before HCC Transplant
3
BOT+BAL Yields Long-Term Survival in Patients With Refractory MSS mCRC
4
MASLD Raises Liver and Other Cancer Risks, Supporting Selective HCC Surveillance
5